Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Dipeptidyl peptidase 9 (DPP9) is a serine protease enzyme that cleaves Xaa-Pro dipeptides from the N-termini of proteins. It plays a role in regulating immunity, energy metabolism, cell survival, proliferation, apoptosis, and adhesion/migration. Unlike DPP4, DPP9 is primarily located in the cytoplasm and nucleus. Altered DPP9 function is linked to type 2 diabetes, obesity, cancer, and immune disorders. It is a key inhibitor of caspase-1-dependent pyroptosis in monocytes/macrophages and interacts with inflammasome regulators like NLRP1 and CARD8. It also interacts with Filamin A and Syk kinase, modulating B-cell signaling.
Inhibition of DPP9 to modulate pyroptosis and downstream signaling pathways.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Dipeptidyl Peptidase 9 (DPP9).